PMGC Holdings (ELAB) Research & Development (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Research & Development came in at $310219.0 in Q2 2026, up 186.34% quarter-over-quarter from $108341.0 in Q1 2026.
Analysis
PMGC Holdings (ELAB) Research & Development (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Research & Development across 5 years of filings, most recently posting $310219.0 for Q2 2026.
- In Q2 2026, Research & Development changed N/A year-over-year to $310219.0; the TTM figure through Jun 2026 stood at $523525.0 (changed N/A YoY), while the FY2025 annual figure was $160376.0, changed N/A from the prior year.
- Research & Development came in at $310219.0 for Q2 2026 at PMGC Holdings, up from $108341.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $89.3 million in Q3 2022 to a low of -$167.7 million in Q4 2022.
- Average Research & Development over 5 years is -$5.8 million, with a median of $108341.0 recorded in 2026.
- Year-over-year, Research & Development plunged 99.9% in 2023 and jumped 439.82% in 2024.
- Over 5 years, Research & Development stood at -$167.7 million in 2022, then surged by 100.21% to $356522.0 in 2023, then plunged by 73.28% to $95260.0 in 2024, then plunged by 57.28% to $40692.0 in 2025, then surged by 662.36% to $310219.0 in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $310219.0 in Q2 2026, $108341.0 in Q1 2026, and $40692.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.88 Bn | 195.89 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.94 Bn | 176.76 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 131.92 Bn | 124.07 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.21 Bn | 56.02 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.53 Bn | 48.39 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.65 Bn | 30.34 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.83 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.64 Bn | 29.64 Bn | 1.16 Mn | 202.02 Mn |
| 10 | PMGC Holdings | 2.25 Mn | -16.54 Mn | 385,691.00 | 310,219.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 310,219.00 |
| Mar 31, 2026 | 108,341.00 |
| Dec 31, 2025 | 40,692.00 |
| Sep 30, 2025 | 64,273.00 |
| Sep 30, 2024 | 95,260.00 |
| Jun 30, 2024 | 721,489.00 |
| Mar 31, 2024 | 393,038.00 |
| Dec 31, 2023 | 356,522.00 |
| Sep 30, 2023 | 86,374.00 |
| Jun 30, 2023 | 133,654.00 |
| Mar 31, 2023 | 102,676.00 |
| Dec 31, 2022 | -167.66 Mn |
| Sep 30, 2022 | 89.33 Mn |